Herpes Zoster, Shingles
Conditions
Keywords
Varicella-zoster vaccine, herpes zoster, shingles, Varicella-zoster virus, postherpetic neuralgia, Herpesviridae Infections, DNA Virus Infections, Virus Diseases
Brief summary
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
Interventions
BIOLOGICALZOSTAVAX™
ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
Sponsors
Kaiser Permanente
Merck Sharp & Dohme LLC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Participants with continuous Kaiser Permanente Northern California (KPNC) membership since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment in KPNC before their study start date
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79 ≥80) at Vaccination | 10 years |
| Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts by Time since Vaccination | 10 years |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79, ≥80) at Vaccination | 10 years |
| Incidence of Postherpetic Neuralgia in Vaccinated and Unvaccinated Cohorts by Time since Vaccination | 10 years |
Outcome results
None listed